Posts

The U.S. Centers for Disease Control and Prevention expects COVID-19 vaccine boosters targeting circulating variants of the virus to be available for children aged 5-11 years by mid-October.

The United States government has sent out over 25 million of the updated COVID-19 booster shots, mostly from Pfizer/BioNTech, as production of the Moderna shot continues to ramp up, a federal health agency said on Tuesday.

Demand for booster vaccinations against COVID-19 is low in Germany, the association of general practitioners said on Thursday, with some patients waiting for a booster designed to combat the currently circulating Omicron BA.4/5 subvariants.

People in Europe should take whatever COVID-19 booster is available to them in the coming months, Emer Cooke, Executive Director of the European Medicines Agency (EMA), said in a Reuters Next Newsmaker interview, ahead of an expected autumn rise in infections.

Israel will offer the updated COVID-19 booster shots from Pfizer/BioNTech designed to combat the Omicron BA.4/5 subvariants by the end of September, a senior health official said on Wednesday.

AstraZeneca Plc on Monday won the dismissal of a U.S. shareholder lawsuit claiming that it concealed problems in developing its COVID-19 vaccine, making it unlikely the treatment would win regulatory approval in the United States.

The European Medicines Agency (EMA) on Monday recommended a COVID-19 booster designed to combat Omicron offshoots BA.4/5, days after endorsing a pair of boosters tailored to target the older BA.1 variant.

The United States is likely to start recommending COVID-19 vaccines annually, health officials said on Tuesday, as new boosters designed to fight currently circulating variants of the coronavirus roll out.

New COVID-19 boosters aimed at fighting currently circulating variants of the coronavirus will be widely available this week, U.S. health officials said on Tuesday, adding that the vaccine is moving closer to an annual jab, as with flu shots.

Pfizer and its German partner BioNTech have filed proceedings at the High Court of England and Wales, seeking a judgment that their COVID-19 vaccine, based on mRNA technology, does not infringe on CureVac’s European patents, according to a regulatory filing on Friday.